Announcement on the consistency evaluation of subsidiary drugs through generic drugs.
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2020-002
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Compliance Evaluation of Subsidiary Drugs Passing Generic Drugs The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Company " ), a controlling subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "" Jianfeng Pharmaceutical "), received the" Drug Supplementary Application Approval "for paroxetine hydrochloride tablets approved and issued by the State Drug Administration (batch number: 2020B02472 ), Jianfeng Pharmaceutical Paroxetine Hydrochloride Tablets have passed the consistency evaluation of generic drug quality and curative effect (hereinafter referred to as" generic drug consistency evaluation "). The relevant information is hereby announced as follows:
1. Drug Basic Information
Drug Name: Paroxetine Hydrochloride Tablets
Dosage Form: Tablet
Specification: 20mg (calculated by C 19 H 20 FNO 3 )
Registration Classification: Chemical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Acceptance No.: CYHB1950106
Batch No.: 2020B02472
Approval Conclusion: according to the provisions of the the People's Republic of China Drug Administration Law, the Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices (Guo Fa (2015 ) 44 ) and the Announcement on Matters Related to the Evaluation of Quality and Efficacy Consistency of Generic Drugs (2017 100 ), after examination, this product has passed the evaluation of quality and efficacy consistency of generic drugs.
OTHER CONDITIONS RELATED TO 2. MEDICINE
(I) FUNCTION INDICATIONS: This product is used to treat depression, obsessive compulsive disorder, panic disorder with or without square terrors, social phobia/ social anxiety disorder. After the curative effect is satisfied, continue to take this product can prevent the recurrence of depression, panic disorder and obsessive-compulsive disorder.
(II) The National Drug Administration received the application for consistency evaluation of the drug in January of 2019 1 .
(III) As of the date of disclosure of this report, the drug research and development investment of about 1289 yuan (unaudited).
(IV) Included in the National Medical Insurance and Basic Drug List: Paroxetine Hydrochloride Tablets have been included in the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug List (2019 Edition ) and classified as Class A; It has been listed in the National Essential Drug List (2018 Edition ) .
(V) the market situation of similar drugs: domestic enterprises that have passed the consistency evaluation of this drug are: Zhejiang Huahai Pharmaceutical Co., Ltd., Beijing Fuyuan Pharmaceutical Co., Ltd., and Sino-US Tianjin SmithKline Pharmaceutical Co., Ltd. In 2018 , the sales of paroxetine hydrochloride tablets in domestic hospitals were about 3.78 .8 billion yuan (data from the database of drug intelligence network). In 2018 , Jianfeng Pharmaceutical achieved a cumulative sales of paroxetine hydrochloride tablets of about 9739.49 yuan.
3. Risk Alert
According to relevant national policies, drug varieties that pass the consistency evaluation will receive greater support in the fields of medical insurance payment and medical institution procurement. If there are more than 3 manufacturers of the same variety of drugs that pass the consistency evaluation of generic drugs, the varieties that do not pass the consistency evaluation of generic drugs will no longer be selected in the centralized procurement of drugs. The Paroxetine Hydrochloride Tablets of Jianfeng Pharmaceuticals has passed the quality and efficacy consistency evaluation of generic drugs, which is conducive to expanding the market share of the drug and enhancing its market competitiveness. As drug sales are affected by national policies, market environment and other factors, there is greater uncertainty. Investors are advised to pay attention to investment risks.
is hereby announced.
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
March 11, 2020
More information
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-30
Peak Pharmaceutical Becomes National Intellectual Property Demonstration Enterprise
Just one year after it was identified as a national intellectual property advantage enterprise in 2016, "Zhejiang Jianfeng Pharmaceutical Co., Ltd." appeared in the list of national intellectual property demonstration enterprises in 2017 recently announced by the State Intellectual Property Office. As a result, Jianfeng Pharmaceutical has become the first and only national intellectual property demonstration enterprise in Jinhua City. On December 12, the State Intellectual Property Office issued a notice to announce the list of national intellectual property demonstration enterprises and advantageous enterprises in 2017. After the enterprise declaration, the recommendation of the provincial and municipal bureaus, the review of the national bureau, and the public announcement, 182 national intellectual property demonstration enterprises and 816 national intellectual property advantage enterprises have been identified. Including Jianfeng Pharmaceutical, Zhejiang Province has been identified as only 15 national intellectual property demonstration enterprises. With the continuous development of enterprises in recent years, Jianfeng Pharmaceutical has set up a special working organization to cultivate and improve the intellectual property ability from the aspects of strategic management, creation, operation and protection of intellectual property rights. It has successively compiled and implemented 27 procedural documents and 36 forms such as "Intellectual Property Management Manual", "Intellectual Property Reward and Punishment System" and "Trade Secret Management System, and timely according to the policy, the current situation of the enterprise to revise, in order to ensure the compliance and effectiveness of the operation of the system. In 2012 and 2013, Jianfeng Pharmaceutical was successively rated as a patent demonstration enterprise in Jinhua City and Zhejiang Province; in 2013, it won the third prize of Jinhua Patent Implementation Award; in 2016, it passed the certification of intellectual property management system and was identified as a national intellectual property advantage enterprise. Currently, Peak Pharmaceuticals has
2020
07-31
Jianfeng Pharmaceutical Approved to Set up Provincial Research Institute
A few days ago, the relevant departments of Zhejiang Province approved the establishment of the provincial research institute of the peak pharmaceutical company. This is another honor won by Jianfeng Pharmaceutical in the field of independent research and development and scientific and technological innovation after the national postdoctoral research workstation and Zhejiang academician expert workstation. The provincial enterprise research institute is a high-level R & D institution led by the Provincial Department of Science and Technology, jointly recognized by the Provincial Economic and Information Commission and the Provincial Development and Reform Commission. As an important part of the national technological innovation system, the Enterprise Research Institute is the core force of the innovation-driven development of Jianfeng Pharmaceutical, which reflects the ability of Jianfeng Pharmaceutical to set up higher-level and higher-level R & D institutions on its own. the ability to gather and integrate innovation elements, organize scientific and technological innovation, support the sustainable development of enterprises, and lead the technological progress of the industry. As a pharmaceutical enterprise, scientific and technological innovation is the eternal theme of enterprise development, and talent is the key to scientific and technological innovation. Over the years, Jianfeng Pharmaceutical has not only focused on cultivating its own scientific research talents, but also established close cooperative relations with well-known universities and scientific research institutions such as China Pharmaceutical University, Shenyang Pharmaceutical University, Sichuan Antibiotic Industry Research Institute, and also focused on introducing top think tanks. In 2011, Professor Liu Jiajian and his team from Sichuan Institute of Antibiotic Industry were introduced, focusing on the technical research of key intermediates of methoxy cephalosporin. In 2013, Professor Shan Weiguang and his scientific research team from Zhejiang University of Technology were introduced to carry out research on preparation technology. In 2015, Professor Wang Guangji, academician of the Chinese Academy of Engineering, was hired as the chief scientist to organize the research on the anti-drug resistance mechanism of national class I new drugs by intracellular pharmacokinetics. In 2017 with Shanghai antibody
2020
07-31
On November 16, the company held the first extraordinary general meeting of shareholders in 2017, which deliberated and passed the proposal on the expiration of the term of the board of directors and the proposal on the expiration of the term of the board of supervisors, and elected a new board of directors and the board of supervisors. The meeting used a combination of on-site registered voting and online voting to vote on director candidates one by one, and elected Jiang Xiaomeng, Du Zihong, Yu Jianhong, Huang Sujian, Liu Bo, Zhang Guoping, Huang Conyun, Sun Hongbin, and Shi Ximin as the company's tenth board of directors. Directors, of which Huang Conyun, Sun Hongbin, and Shi Ximin are independent directors. The meeting used a combination of on-site registered voting and online voting to vote on supervisor candidates one by one, and elected Chen Tianci, Lu Ruimei, and Shi Fu as supervisors of the company's ninth board of supervisors. Prior to this, the company's trade union held an enlarged meeting of the trade union committee to elect Qin Xuping and Jin Huazhong as employee representative supervisors of the ninth board of supervisors. On the same day, the company's tenth board of directors held its first meeting and elected Jiang Xiaomeng as the chairman of the tenth board of directors. Jiang Xiaomeng, Du Zihong, Huang Sujian, Sun Hongbin and Shi Ximin were elected as members of the Strategy Committee of the 10th Board of Directors, and Jiang Xiaomeng was the chairman of the Strategy Committee. Shi Ximin, Huang Conyun and Jiang Xiaomeng were elected as members of the audit committee of the 10th board of directors, and Shi Ximin was the chairman. Sun Hongbin, Huang Conyun and Jiang Xiaomeng were elected as members of the nomination committee of the 10th board of directors, and Sun Hongbin was the chairman. Huang Cong Yun, Shi Ximin and Du Zihong were elected as members of the remuneration and assessment committee of the 10th board of directors, and Huang Cong Yun was the chairman. The board of directors appointed Yu Jianhong as the general manager of the company and appointed Huang Jinlong.
2020
07-31
Peak natural products pollution control results by the industry attention
As a leader in China's plant extracts industry, Tianjin Jianfeng Natural Products Company has achieved fruitful results in technological innovation. On October 26 and 27, at the 2017 Forum on improving the international competitiveness of China's plant extract industry held in Handan City, Hebei Province, Liu Dan, general manager of the company, delivered a speech entitled "prevention and control of water pollution in the field of plant extraction", introducing the successful experience of sewage treatment in the past five years, which was widely concerned by the participants. In recent years, environmental protection and ecology have become hot words for the development of enterprises and society. Due to the particularity of the plant extraction industry, pollution control in this industry has different characteristics and requirements from ordinary production enterprises. For example, sewage presents higher chroma, extremely low PH value, more suspended solids, high salinity, high concentration of COD, and different sewage water quality of different products. As the earliest enterprise producing opc grape seed extract in China, Natural Products Company has always attached great importance to the pollution control of plant extraction. For example, in the sewage treatment upgrading project implemented in 2016, ozone oxidation and biochemical methods were adopted to remove the remaining organic pollutants, increasing the sewage treatment capacity from 200 cubic meters per day to 500 cubic meters. The latest anaerobic sewage treatment technology is adopted, the COD emission value of the outlet is reduced to 60 mg per liter, which is far lower than the national first-class emission standard of 100 mg per liter. The new system adopts advanced oxidation reaction tower, ozonation method, field energy reactor and sludge adsorption reflux technology, which can quickly and efficiently treat organic pollutants with strong chemical stability without adding any chemicals.
2020
07-31